10-Q: Sonoma Pharmaceuticals Reports First Quarter 2025 Results with Mixed Regional Performance

Sonoma Pharmaceuticals reported a net loss of $1.143 million for the quarter ended June 30, 2024, with revenue slightly down compared to the same period last year.

Summary

• Sonoma Pharmaceuticals reported a net loss of $1.143 million for the three months ended June 30, 2024, compared to a net loss of $1.418 million for the same period in 2023.
• Revenue for the quarter was $3.391 million, a slight decrease from $3.427 million in the prior year.
• The company's gross profit increased to $1.306 million from $1.204 million year-over-year.
• Operating expenses totaled $2.479 million, compared to $2.444 million in the prior year.
• The company's working capital was $8.176 million as of June 30, 2024, down from $8.829 million at the end of March 2024.
• Net cash used in operating activities was $912,000 for the quarter, compared to $215,000 in the same period last year.
• The company sold 3,166,202 shares of common stock for net proceeds of $748,000 during the quarter.
• The company has a substantial accumulated deficit of $195.492 million as of June 30, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed results with a slight decrease in revenue and a net loss, coupled with increased operating cash burn and a decrease in working capital. While there are some positive aspects like increased gross profit and cost containment, the overall financial health and going concern risks temper the sentiment.

Positives

• Gross profit increased to $1.306 million, up from $1.204 million year-over-year, indicating improved profitability on sales.
• Selling, general and administrative expenses decreased by $110,000 due to cost containment efforts.
• The company raised $748,000 through the sale of common stock, providing additional capital.
• Revenue in Europe increased by $218,000, showing growth in that region.
• Latin America revenue increased by $393,000 due to timing of customer orders.

Negatives

• The company reported a net loss of $1.143 million for the quarter.
• Overall revenue decreased slightly to $3.391 million from $3.427 million in the prior year.
• Net cash used in operating activities increased significantly to $912,000 from $215,000 in the prior year.
• Working capital decreased to $8.176 million from $8.829 million at the end of the previous quarter.
• Revenue in the United States decreased by $164,000.
• Revenue in Asia decreased by $385,000.
• Revenue in the Rest of the World decreased by $98,000.

Risks

• The company has a history of losses and an accumulated deficit of $195.492 million, raising concerns about its ability to continue as a going concern.
• The company relies on a few key customers for a significant portion of its revenue, creating concentration risk.
• The company is exposed to foreign currency devaluation risks, particularly with the Mexican Peso and the Euro.
• The company faces a substantial tax liability in Mexico due in 2027.
• The company is monitoring the impact of inflation, increased volatility in financial markets, shipping costs, supply chain issues, and labor costs.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company may face difficulties retaining and finding qualified employees in a tight labor market.

Future Outlook

The company believes it has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means, but there is no assurance that such financing will be available on commercially acceptable terms. The company may need to reduce costs if additional capital is not secured.

Management Comments

• Management believes that the company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means.
• Management is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.
• Management believes there are sufficient assets on the balance sheet to more than cover any tax obligation without interrupting our operations or business.

Industry Context

The company operates in the healthcare sector, specifically in wound care, dermatology, and disinfectant markets. The company's focus on hypochlorous acid (HOCl) products positions it within a niche market that emphasizes safety and efficacy. The company faces competition from other companies developing and selling similar products.

Comparison to Industry Standards

• Sonoma Pharmaceuticals competes with companies like Acelity (now part of 3M) in the advanced wound care market, which has seen significant growth due to an aging population and increasing incidence of chronic wounds.
• In the dermatology space, companies like Galderma and LEO Pharma are major players, focusing on prescription and over-the-counter treatments for various skin conditions.
• For disinfectants, companies like Ecolab and Diversey are key competitors, offering a wide range of solutions for healthcare and industrial settings.
• Sonoma's focus on HOCl technology differentiates it from traditional antiseptic and disinfectant products, but it must demonstrate its products' superiority in clinical outcomes and cost-effectiveness to gain market share.
• Compared to larger pharmaceutical companies, Sonoma's revenue is relatively small, and it relies heavily on partnerships for distribution and sales, which can impact its profitability and market reach.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, including matters involving proprietary technology.

Stakeholder Impact

• Shareholders may be concerned about the company's continued losses and the material weaknesses in internal controls.
• Employees may be affected by potential cost-cutting measures if the company is unable to secure additional capital.
• Customers may be impacted by potential supply chain issues and changes in product pricing.
• Creditors may be concerned about the company's ability to repay its debts given its financial condition.

Next Steps

• The company will continue to monitor and address the material weaknesses in internal controls.
• The company will continue to evaluate its end-to-end supply chain and assess opportunities to refine the impact on sales.
• The company will continue to engage tax professionals to review all options to limit exposure to the Mexico tax liability.

Key Dates

Keywords

hypochlorous acid, wound care, dermatology, healthcare, pharmaceuticals, HOCl, skin care, disinfectant, animal health, revenue, net loss, financial results